Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

2.780 +0.070 (+2.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,361,893
Open 2.800
Bid (Size) 2.690 (100)
Ask (Size) 2.780 (200)
Prev. Close 2.710
Today's Range 2.730 - 2.830
52wk Range 1.120 - 3.105
Shares Outstanding 70,417,345
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+58.0%
+58.0%
1 Month
+9.4%
+9.4%
3 Month
+12.1%
+12.1%
6 Month
+50.3%
+50.3%
1 Year
+109.0%
+109.0%

More News

Read More
News headline image
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters ↗
Via Chartmill
News headline image
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Here's Why Ovid Therapeutics Stock Popped Higher Today ↗
Via The Motley Fool
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
OVID THERAPEUTICS INC (NASDAQ:OVID) Announces Leadership Transition and Key Pipeline Milestones Following Q3 2025 Results ↗
Via Chartmill
News headline image
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why ↗
Via Stocktwits
Topics Intellectual Property
News headline image
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill

Frequently Asked Questions

Is Ovid Therapeutics Inc. - Common Stock publicly traded?
Yes, Ovid Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Ovid Therapeutics Inc. - Common Stock trade on?
Ovid Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ovid Therapeutics Inc. - Common Stock?
The ticker symbol for Ovid Therapeutics Inc. - Common Stock is OVID on the Nasdaq Stock Market
What is the current price of Ovid Therapeutics Inc. - Common Stock?
The current price of Ovid Therapeutics Inc. - Common Stock is 2.780
When was Ovid Therapeutics Inc. - Common Stock last traded?
The last trade of Ovid Therapeutics Inc. - Common Stock was at 09/03/26 04:00 PM ET
What is the market capitalization of Ovid Therapeutics Inc. - Common Stock?
The market capitalization of Ovid Therapeutics Inc. - Common Stock is 195.76M
How many shares of Ovid Therapeutics Inc. - Common Stock are outstanding?
Ovid Therapeutics Inc. - Common Stock has 196M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.